Form 4: Harrow Inc. Chief Scientific Officer Awarded Stock Options

Harrow Inc.'s Chief Scientific Officer, Amir Shojaei, was granted 30,000 stock options on January 6, 2025, which vest over four years.

Summary

• Amir Shojaei, the Chief Scientific Officer of Harrow Inc., was granted 30,000 stock options.
• The options have an exercise price of $35.96 per share.
• The options vest over a four-year period, with 25% vesting after one year and the remaining 75% vesting in equal quarterly installments over the following three years.
• The options become fully vested and exercisable on January 6, 2029.
• The options expire on January 6, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management interests with shareholders. There is no indication of any negative sentiment.

Positives

• The grant of stock options aligns the Chief Scientific Officer's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

Stock option grants are a common form of executive compensation in the pharmaceutical and biotechnology industries, used to incentivize performance and retain key talent.

Comparison to Industry Standards

• Stock option grants are a standard practice for executive compensation across various industries, particularly in high-growth sectors like biotechnology.
• Vesting schedules, such as the four-year period with a one-year cliff followed by quarterly vesting, are typical for these types of grants.
• The exercise price of $35.96 would be compared to the current market price of the stock to determine the value of the options.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the Chief Scientific Officer to contribute to the company's long-term success.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, executive compensation, insider trading, Harrow Inc., Amir Shojaei, vesting